


HARBIGE et al  
Appl. No. 10/756,761  
January 2, 2009

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (currently amended). A method of treating a patient in need of therapy for multiple sclerosis comprising administering to that patient a therapeutically effective dose between 400500mg/day and 700mg/day of a compound of formula I



wherein R¹, R², R³, R⁴ and R⁵ are independently selected from the group consisting of hydrogen, trihaloalkyl and halo substituents;

X¹, X² and X³ are independently selected from the group consisting of CH, CCH<sub>2</sub>F, CCF<sub>3</sub>, CO alkyl and CCH<sub>3</sub>, and nitrogen atoms, with at two of X¹, X² and X³ being nitrogen, alkyl being preferably ethyl, ethyl or propyl; and Y¹ and Y² are independently selected from the group consisting of hydrogen and primary, secondary NH<sub>2</sub> and tertiary amino groups wherein the tertiary amino groups are selected from -1-piperazinyl and 4-alkyl-1-piperazinyl.

HARBIGE et al  
Appl. No. 10/756,761  
January 2, 2009

2 (original). A method as claimed in Claim 1 wherein R<sup>1</sup> to R<sup>6</sup> are independently selected from hydrogen and chloro, with two or three of R<sup>1</sup> to R<sup>5</sup> being chloro.

3 (original). A method as claimed in Claim 1 wherein X<sup>1</sup>, X<sup>2</sup> and X<sup>3</sup> are nitrogen.

4-5 (cancelled).

6 (original). A method as claimed in Claim 1 wherein Y<sup>1</sup> is selected from -NH<sub>2</sub>, -1-piperazinyl and 4-alkyl-1-piperazinyl and Y<sup>2</sup> is -NH<sub>2</sub>.

7 (original). A method as claimed in Claim 1 wherein the compound of formula 1 is selected from the group consisting of Lamotrigine: 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine, Sipatrigine: 4-amino-2-(4-methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)-pyrimidine, 2,4-diamino-5-(2,3-dichlorophenyl)-6-(fluoromethylpyrimidine), R(-)-2,4-diamino-6-(fluoromethyl)-5-(2,3,5-trichlorophenyl)-pyrimidine, 4-amino-2-(1-piperazinyl)-5-(2,3,5-trichlorophenyl)-pyrimidine (active Sipatrigine metabolite), 4-amino-2-(4-methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)-6-trifluoromethylpyrimidine, 2,4-diamino-5-(2,3,5-trichlorophenyl)-trifluoromethylpyrimidine, 2,4-diamino-5-(2,3,5-trichlorophenyl)-6-methoxymethylpyrimidine, 4-amino-6-methyl-2-(4-methyl-1-piperazinyl)-5-(2,3,5-

HARBIGE et al  
Appl. No. 10/756,761  
January 2, 2009

trichlorophenyl)-pyrimidine, 4-amino-2-(4-propyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)-pyrimidine and 2,4-diamino-5-(2,3,5-trichlorophenyl)-pyrimidine.

8 (original). A method as claimed in Claim 1 wherein the therapy results in reduction of one or more of incidence of relapse, spasticity and fatigue.

9 (original). A method as claimed in Claim 1 wherein the therapy stabilises the patients Expanded Disability Status Score (EDSS), thus halting progress of the disease.

10 (original). A method as claimed in Claim 1 wherein the compound of formula 1 is administered during periods of remission, as well as during relapse, such that the occurrence of relapse is reduced.

11 (original). A method as claimed in Claim 1 wherein the compound of formula 1 is given at a dose sufficient to reduce spasticity or daytime fatigue.

12-13 (cancelled).

14 (original). A method as claimed in Claim 1 wherein the compound of formula 1 is administered at a dose of about 600mg/day.

HARBIGE et al  
Appl. No. 10/756,761  
January 2, 2009

15 (original). A method as claimed in Claim 1 wherein the compound is administered in an escalating dosing regime, starting at 100mg/day or less and escalating to the maximum treatment dose over a period of 1 to 10 weeks.